Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04301843
Title Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Giselle Sholler
Indications

neuroblastoma

Therapies

Eflornithine + Etoposide

Age Groups: adult | child
Covered Countries USA | CAN


No variant requirements are available.